Undercover Operative: Environmental Microbiologist Infiltrates the World of Human Microbiome Research 

Undercover Operative: Environmental Microbiologist Infiltrates the World of Human Microbiome Research 

Undercover Operative: Environmental Microbiologist Infiltrates the World of Human Microbiome Research 

BTI Researcher Christopher Staley uses an ecology framework to tackle the human microbiome and its intricate secrets. 

By Emerson Mehring

Can your poop cure disease? Sounds ridiculous until you hear stories from patients helped by a fecal microbiota transplant (FMT). BTI Researcher Christopher Staley left the banks of the Mississippi River and dove head first into the diverse ecosystem living inside our digestive tract: the microbiome. But how did he get there?

During his undergraduate and graduate studies, Staley met Michael Sadowsky, a distinguished microbiologist and then director of the University of Minnesota BioTechnology Institute. After mingling at several research conferences, Sadowsky offered Staley a job studying water quality at pollution sites along the Mississippi River. Staley’s role was to isolate and analyze DNA sequences from microorganisms living in the water and sediment.

With no expertise in mathematical modeling for biological systems or computational biology, Staley was concerned about his new position, but Sadowsky reassured him he was a good fit. Staley offered a new perspective to the team of bioinformatic scientists that would process the data. He understood the connections to the larger ecosystem.

“I learned how to speak both languages,” recounts Staley. “And we found eight stories hidden in their data which were all eventually published.”

Much like the waters of the Mississippi, the digestive tract harbors countless microbial communities. When Sadowsky introduced Staley to fellow BTI researcher Alexander Khoruts’ work on the microbiome, a natural partnership emerged. 

Khoruts and Sadowsky were instrumental in developing the modern use of microbiota transplant therapeutics (MTT), though the practice dates to fourth-century China when people suffering from severe diarrhea were treated using a soup of dried fecal matter (yes, you read that correctly) to restore the balance of bacteria in the gut. Khoruts and Sadowsky sought a modern approach to help patients suffering from stubborn Clostridium difficile infections that cause severe stomach cramping, diarrhea, and abdominal pain. But faced with the complexity of the microbiome, Khoruts and his team had many unanswered questions.

After analyzing their dataset, Staley recognized that environmental science offered some solutions. “The tools and techniques we used studying the river are the same for fecal samples. They thought their questions were hard, but I saw them through a different lens.” He recalls the collaboration as a success because they respected each other’s expertise, which presented complementary analytical perspectives. 

After dabbling in clinical research, Staley’s curiosity was piqued, so he pursued a position in the Department of Surgery at the University of Minnesota. 

Navigating the transition from environmental to clinical research was challenging. Staley built on his background in ecology to explore links between the microbiome and human disease while working with University of Minnesota physician Armin Rashidi, who studies the effects of leukemia treatment on the microbiome. 

Knowing that antibiotics can wreak havoc on the microbial balance in the body, Rashidi sought to understand the potential impact on his patients. Working together, Rashidi and Staley determined that antibiotics—while effective in treating harmful infections—also destroyed the helpful bacteria that keep our bodies healthy. This paradox proved fundamental to understanding the connection between the microbiome and disease and how microbial communities interact to support and undermine human health.

The microbiome has been linked to obesity, colorectal cancer, and almost every illness researchers could find. And while microbiome research has blossomed over the last decade, Staley estimates about 15 percent of studies pay adequate attention to microbial community function, and even fewer explore a critical component of bacterial communication: quorum sensing. Staley’s new focus is on disrupting the signaling molecules bacteria use to communicate with quorum quenching techniques, in collaboration with BTI investigator Mikael Elias, which prevent synchronized behavior in microbial communities.

“Of course, they’re talking in there,” says Staley. “Did you think the bacteria were just sitting there, ignoring each other? There are trillions of them!”

In preliminary testing in mice, Staley found evidence that quorum sensing could play a significant role in the gut-body connection. When fed a Western diet, quorum-quenching mice were more resistant to diet-induced obesity than mice in the control group. While only a preliminary trial, Staley is enthusiastic about digging into the mechanics of bacterial communication and its impact on the human body. 

Does he miss the Mississippi and his work in environmental science? Staley’s lab is a short walk from the mighty river, and as he points out: “First, I was looking for the effects of pollutants on a body of water, and now I’m analyzing fecal matter for how bacteria impact the body … it’s almost the same!”

Schedule

Schedule


Friday May 5, 2023

(One day symposium)

McNamara Alumni Center
University of Minnesota
Minneapolis, MN USA.

Map & Directions

 Symposium Time Table

 

9:00-9:15

 

Opening Messages

  • Professor Romas Kazlauskas  (UMN)
  • Professor Ismail (PPIC)
  • President Amano (Video message: Amano Enzyme Japan)

9:15-9:45

9:45-10:15

10:15-10:45

10:45-11:15

Presentation 1

Presentation 2

Presentation 3

Presentation 4

11:15-12:00 Panel discussion
12:00-13:30

Lunch
Poster session

13:30-14:00

14:00-14:30

14:30-15:00

Presentation 5

Presentation 6

Presentation 7

15:00-15:20 Coffee Break

15:20-15:50

15:50-16:20

16:20-16:50

Presentation 8

Presentation 9

Presentation 10

16:50-16:55

 

Messages from Dr. Shotaro Yamaguchi (Amano Enzyme Japan)
17:00-18:30 Cocktail hour

 

Presenters

Romas Kazlauskas

Romas Kazlauskas, Ph.D.

Professor, Biochemistry, Molecular Biology & Biophysics
Biotechnology Institute
University of Minnesota
rjk@umn.edu

Romas Kazlauskas studied chemistry at the Massachusetts Institute of Technology (Ph.D.) and Harvard University (postdoc with George Whitesides). He worked at General Electric Company (1985-88) and McGill University, Montreal, Canada (1988-2003) and is currently a professor in Biochemistry, Molecular Biology and Biophysics at the University of Minnesota. He has been a visiting professor in Germany, Sweden and South Korea. He is an expert in protein engineering of enzymes for biocatalysis and the author of a forthcoming textbook on protein engineering (www.betterenzyme.com).

 Research Interests

  • Engineering new catalytic activity in enzymes
  • Rational design of enzyme properties
  • Enzyme applications to support sustainability
Shotaro Yamaguchi

Shotaro Yamaguchi, PhD.

CTO, Managing Director of Innovation
Amano Enzyme Inc.
shotaro_yamaguchi@amano-enzyme.com

Shotaro Yamaguchi joined Amano in 1984 after receiving a master’s degree in food engineering from the Graduate School of Agriculture, Kyoto University. Since then, he has been engaged in industrial enzymology, fungal genetic engineering, microbial fermentation, and food and medical enzyme applications. He received Ph.D. degree from Kyoto University on lipase in 1991 and spent three years at the Institute of Food Research (UK) from 1999 to 2001. He discovered a novel protein-modifying enzyme, protein glutaminase.

He received the following awards: Encouragement Award from Brewing Society of Japan (2003) and Technology Award from Japan Society for Bioscience, Biotechnology, and Agrochemistry (2010). He is an active Editor for Applied Microbiology and Biotechnology, Headquarters Officer/Auditor for Japan Society for Bioscience, Biotechnology, and Agrochemistry, and Representative for The Society for Biotechnology, Japan.

Todd Hester

Todd Hyster, Ph.D.

Associate Professor
Department of Chemistry and Chemical Biology
Cornell University
 

Prof. Todd Hyster is an Associate Professor of Chemistry and Chemical Biology at Cornell University. He received his B.S. in Chemistry from the University of Minnesota. He did his Ph.D. studies with Tomislav Rovis at Colorado State University. As part of his Ph.D., he was a Marie Curie Fellow with Thomas Ward at the University of Basel. He was an NIH Postdoctoral Fellow with Prof. Frances Arnold at Caltech. He started his independent career at Princeton University in 2015. His group has developed new methods in photoenzymatic catalysis.

Research Interests
  • Photoenzymatic Catalysis
  • Enzyme engineering via directed evolution
  • Selective organic synthesis

Photoenzymatic Catalysis – Using Light to Reveal New Enzyme Functions
Todd K. Hyster

Enzymes are exquisite catalysts for chemical synthesis, capable of providing unparalleled levels of chemo-, regio-, diastereo- and enantioselectivity. Unfortunately, biocatalysts are often limited to the reactivity patterns found in nature. In this talk, I will share my groups efforts to use light to expand the reactivity profile of enzymes. In our studies, we have exploited the photoexcited state of common biological cofactors, such as NADH and FMN to facilitate electron transfer to substrates bound within enzyme active sites. In other studies, we found that enzymes will electronically activate bound substrates for electron transfer. In the presence of common photoredox catalysts, this activation can be used to direct radical formation to enzyme active sites. Using these approaches, we can develop biocatalysts to solve long-standing selectivity challenges in chemical synthesis.

    Stefan Lutz

    Stefan Lutz, Ph.D.

    Sr VP Research
    Codexis Inc.
    stefan.lutz@codexis.com

    Stefan received a B.Sc. in chemistry/chemical engineering from the Zurich University of Applied Sciences, an M.Sc. in Biotechnology from the University of Teesside and a Ph.D. in chemistry from the University of Florida. He was a postdoctoral fellow at Pennsylvania State University. He joined Codexis in 2020 as the Senior Vice President of Research to lead the company’s research team advancing the technology platform, as well as the discovery and engineering of novel enzymes. Prior to his arrival in Redwood City, he was a Professor and Chair of the Chemistry Department at Emory University, having joined the university in 2002 and ascending to Chemistry Department Chair in 2014. Stefan is interested in advanced technologies for creating new, innovative, and economically-sustainable enzyme solutions to benefit society, industry, and the planet.

    Research Interests

    • Advanced technologies for enzyme design and engineering
    • Engineered enzyme applications
    • Biocatalysis

    Engineering Enzyme Products
    Stefan Lutz

    Codexis’ CodeEvolver® directed evolution technology has been applied to improve enzymes for specific functions for well over a decade. Advances in high-throughput gene & protein synthesis (build) and biochemical screening (test) in combination with advanced data analytics (learn) and computational design tools have, and continue to, enable the optimization and drive increasing complexity in developing novel biocatalysts for sustainable manufacturing, the life sciences, and the discovery and optimization of biologics.

    Tomoko Matsuda, Ph.D.

    Associate Professor
    Department of Life Science and Technology
    Tokyo Institute of Technology
    tmatsuda@bio.titech.ac.jp

    Tomoko Matsuda received a doctoral degree in science from Kyoto University (2000). Her doctoral thesis is about the biocatalytic asymmetric reduction of ketone for organic synthesis. She has been engaged in research on biocatalysis since then. She was appointed as an assistant professor at Ryukoku University in Japan (1999-2004) and began the study for biocatalysis using pressurized carbon dioxide. She was appointed as an associate professor in 2004 at the Tokyo Institute of Technology in Japan. She published over 130 scientific articles and received the following awards; the Taisho Pharmaceutical Research Planning Award from the Society of Synthetic Organic Chemistry, Japan (2001), the Morita Scientific Research Encouragement Award from the Japanese Association of University Women (2006), the Shiseido Woman Researcher Science Grant from Shiseido (2011), the Takeda International Contribution Award from Takeda Rika Kogyo (2018).

    Research Interests

    • Utilization of pressurized CO2 for biocatalysis
    • Green chemistry using biocatalysis

    Utilization of Carbon Dioxide as Solvent and Substrate for Biocatalysis
    Tomoko Matsuda

    As carbon dioxide (CO2) is an abundant carbon source and is causing global warming, developments in its utilization methods have been awaited. Therefore, pressurized CO2such as supercritical CO2 has been applied as a solvent for organic synthesis to develop efficient reactions replacing ordinary organic solvents derived from fossil fuel. However, the application of pressurized CO2 to biocatalysis has been limited. Therefore, we have been studying on utilization of CO2 as a solvent for lipase-catalyzed transesterification reactions and as a substrate for biocatalytic carboxylation reactions.

    Supercritical and liquid CO2 has been used for lipase-catalyzed transesterifications to replace conventional organic solvents. In this study, CO2-expanded liquids, liquids expanded by dissolving pressurized CO2, were utilized since they can be achieved at a lower pressure than supercritical and liquid CO2. Then, we found that for lipase-catalyzed transesterifications of bulky substrates, such as 1-(1-adamantyl)ethanol, o-substituted 1-phenylethanol analogs, and substituted 1-tetralol analogs, the conversions were higher for the reaction in CO2-expanded liquids than those in the corresponding liquids without CO2 (Figure 1).

    Matsuda Figure 1

    Figure 1 Solvent engineering using CO2 for lipase-catalyzed transesterifications

    On the other hand, a two-layer solvent system consisting of an aqueous buffer and the carbon dioxide layer was utilized for the carboxylation reactions since carboxylation enzymes are not stable in pressurized CO2 without bulk water. Catalyzed by enzymes from a thermophilic microorganism, Thermoplasma acidophilum isocitrate dehydrogenase (TaIDH) and T. acidophilum glucose dehydrogenase (TaGDH), the reductive carboxylation reactions have been successfully conducted using CO2 as a substrate (Figure 2). These enzymes were also co-immobilized to achieve higher stabilities and activities by forming an enzyme-inorganic hybrid nanocrystal.

    Matsuda Figure 2

    Figure 2 Utilization of CO2v as a substrate of biocatalytic carboxylation

    Anne Meyer

    Anne Meyer, Ph.D.

    Anne S. Meyer is Professor of Enzyme Technology, Head of the Protein Chemistry & Enzyme Technology Section at Dept. of Biotechnology and Biomedicine, Technical University of Denmark. The Section comprises 8 professor research groups, in total ~75 persons, incl. ~20 PhD students. She is group leader of Enzyme Technology in the Section.

     
    Research interests:

    • Applied enzyme technology, incl. enzyme enzymatic biorefining of biomass, agro-industrial side streams, starch, pectin, and seaweeds for production of bioactives and functional food compounds.
    • Enzymatic synthesis of human milk oligosaccharides.
    • Enzymatic degradation of plastic, and enzymatic conversion of CO2.
    • Bioinformatics, enzyme characterization, assays, kinetics, and carbohydrate chemistry

    New food processes and ingredients via targeted enzyme catalysis
    Anne S. Meyer, Technical University of Denmark, Denmark

    One of the major challenges confronting the modern food supply chain is providing safe, nutritious, and preferably functionally healthy food to an expanding global population while utilizing resources sensibly and protecting the environment and the climate. Many agro-industrial co-processing streams are rich in complex plant fibers that should not go to waste, as they may be a valuable source of beneficial, ‘prebiotic’ dietary fibers or a feedstock for functional ingredients production. Corn bran, a residue from large scale corn starch processing, is for example rich in highly substituted feruloylated glucurono-arabinoxylan, and even includes diferuloyl cross links, and is considered recalcitrant to enzymatic modification. We recently discovered a bacterial endo-xylanase (GH30 from Dickeya chrysantemi) that attacks complex corn arabinoxylan to enable gentle solubilization of substituted glucurono-arabinoxylan oligomers1. The recent news is that the GH30-solubilized corn arabinoxylan molecules modulate the human gut microbiota during simulated colon fermentation in vitro, paving the way for using corn bran streams as a resource to generate new soluble prebiotics2. Human milk oligosaccharides (HMOs) are unique, beneficial oligosaccharides in human breast milk. Enzymatic synthesis of HMOs is attractive to create new additives for infant formula and other products. Several glycoside hydrolases can catalyze transglycosylation (incl. transfucosylation) for precise enzymatic synthesis of nature-identical HMO products3. To attain high yields, we are using different types of protein engineering approaches to modify the enzyme to catalyze relevant transglycosylations at high yield4. Citrus-pectin residues have turned out to hold fucosylated xyloglucan that can serve as a source of fucose for enzymatic production of fucosylated HMOs via targeted enzymatic transfucosylation5. Seaweeds, i.e. marine macroalgae, have for decades been a source of food hydrocolloids. As the demand for hydrocolloids keep increasing, kelp seaweeds are now cultivated in the Northern hemisphere and new enzymes are being discovered for enzymatic refining options for kelp biorefining beyond extraction of hydrocolloids. One line of our research relates to enzymatic modification of alginate from kelp6, another concerns enzymatic extraction and modification of fucoidan for medical uses7,8,9. Lastly, we have recently introduced  new microbial 4-alpha-glucanotransferases to modify starch functionality10.

     

    1. Munk et al., 2020. ACS Sust Chem Eng 8 (22), 8164-8174.
    2. Lin et al. 2023. J Agric Food Chem 71, 385-3897
    3. Zeuner and Meyer 2020. Carb Res 493, 108029.
    4. Zeuner et al. 2020 J of Fungi 6(4), 295-313
    5. Nielsen et al. 2022. Carb Res. 519, 198627
    6. Pilgaard et al. 2021. J of Fungi 7, 80-95.
    7. Nguyen et al. 2020. Marine Drugs 18(6), 296-313
    8. Trang et al. 2022. Frontiers Plant Sci 13, 823668
    9. Ohmes et al. 2020 Marine Drugs 18, 481-418
    10. Christensen et al. 2023. Intl J Biol Macromol 224, 105-114.

     

    Jun Ogawa, Ph.D.

    Professor
    Division of Applied Life Sciences,
    Graduate School of Agriculture,
    Kyoto University
    ogawa.jun.8a@kyoto-u.ac.jp

    Jun Ogawa studied applied microbiology and completed his doctorate in 1995 at Kyoto University and became an assistant professor at the same university. He was a visiting researcher at French National Institute for Agricultural Research (INRA) (2006-2007) and has appointed as a full professor of the current position in 2009. He has published over 270 papers in applied microbiology such as bioprocess development, microbial metabolism analysis, etc. He was awarded “Agrochemistry Award for the Encouragement of Young Scientists” by Japan Society for Bioscience, Biotechnology, and Agrochemistry (2006), “Oleoscience Award” by the Japan Oil Chemists’ Society (2015 and 2020), “Society Award of Japanese Association for Food Immunology” (2018), “Ching Hou Biotechnology Award” (2020) and “Fellow” (2021) by American Oil Chemists’ Society, and “Chevreul Medal” by the French association for the study of lipids (2021).

    Research Interests

    • Microbial physiology
    • Fermentation technology
    • Enzyme technology
    • Metabolic engineering
    • Microbial consortia studies

     
    From function to genes, enzymes, and communities; creating novel biotechnology tools
    Jun Ogawa

    Information obtained through detail analysis of microbial function leads to finding of unexpected enzymes, metabolisms, and communities useful for bioprocess design. The screening of the novel biotechnological tools required analysis of unrevealed function with difficulties in establishing the methods, however, recent omics technologies make easier to identify the novel genes, enzymes, and communities, expanding their bioprocess application. Here, examples of bioprocess development by applying unique tools found through functional analysis of microbial metabolisms are introduced.

    1)  Novel amino acid metabolism involving hydroxylase- and dehydrogenase- catalyzing reactions was found. The hydroxylase library expanded through genomic information analysis and coupled with related enzymes made possible the production of various chiral hydroxy amino acids and chiral amino acid sulfoxides1,2.

    2)  Novel fatty acid reducing metabolism, polyunsaturated fatty acid (PUFA) saturation metabolism, was found in gut microorganisms. The metabolism involving four enzymes of hydratase, dehydrogenase, isomerase, and reductase was applied to the production of various hydroxy, oxo, and enone fatty acids with unique physiological activity useful for health3. Novel desaturases involved in PUFA biosynthesis4, and cyclooxygenase5 and P450 monooxygenase6 generating PUFA-derivatives were found and applied to the production of physiologically active PUFA derivatives.

    3)  Novel nucleosidases acting on 2’-O-methylribonucleosides were found and their ribosyl transferring activity was applied for the production of 2’-O-methylribonucleosides7. A novel enzyme, allantoinase, in the purine degradation metabolism was found to useful for the production of chiral amides via prochiral cyclic imide hydrolysis8. The reversible reactions involved in nucleoside degradation metabolism were applied to produce deoxyribonucleosides9.

    4)  Phytochemicals in foods and medicines are changed into bioactive molecules by gut microbial metabolism. The analysis of gut microbial metabolism of phytochemicals such as glucosinolates10, ellagic acid11, baicalin12, and astragaloside IV13 resulted in finding of novel enzymes. Besides, novel aglycon-glycosylating enzymes were found in microorganisms and applied to enhance the applicability of phytochemicals14,15.

    5)  Nitrifying bacteria play an important role in generating nitrate for crop cultivations. Organic nitrogen compounds are converted to nitrate through ammonification and nitrification. Understanding the interactions of the nitrifying microbial consortia is important for controlling the mineralization of organic nitrogen compounds. We established a controllable model consortium for ammonification and nitrification under organic conditions using a co-culture of only three strains selected through metagenomic analysis16,17. 

    References

    1. Hibi, M. et al. Appl Microbiol Biotechnol, 97, 2467-2472 (2013))
    2. Hibi, M. et al. Commun Biol, 4:16 (2021).)
    3. Kishino, S. et al. Proc Natl Acad Sci USA, 110, 17808-17813 (2013))
    4. Mo, B. K. H. et al. Biosci Biotechnol Biochem, 85, 1252–1265 (2021))
    5. Mohd Fazli, F. A. et al. Biosci Biotechnol Biochem, 83, 774-780 (2019))
    6. Saika, A. et al. FASEB Bioadv, 2, 59-71 (2020))
    7. Mitsukawa, Y. et al. J Biosci Bioeng, 125, 38-45 (2017))
    8. Nojiri, M. et al. Appl Microbiol Biotechnol, 99, 9961-9969 (2015))
    9. Horinouchi, N. et al. Microbial Cell Factories, 11, 82, (2012))
    10. Watanabe, H. et al. Sci Rep, 11, 23715, (2021))
    11. Watanabe, H. et al. J Biosci Bioeng, 129, 552-557 (2020))
    12. Sakurama, H. et al. Appl Microbiol Biotechnol, 98, 4021-4032 (2014))
    13. Takeuchi, D. M. et al. Biosci Biotechnol Biochem, 86(10) 1467–1475 (2022))
    14. Suzuki, T. et al. Biocatal Agric Biotechnol, 30, 101837 (2020))
    15. Kimoto, S. et al. J Biosci Bioeng, 134, 213-219 (2022))
    16. Saijai, S. et al. Biosci Biotechnol Biochem, 80, 2247-2254 (2016))
    17. Meeboon, J. et al. Sci Rep, 12, 7968 (2022)

    Synthetic Cells and Biofactories

    Synthetic Cells and Biofactories

    Synthetic Cells and Biofactories

    Kate Adamala and the Build-a-Cell consortium look to synthetic biology for insight into the origins of life and a source for vital raw materials.

    By Bernard Cook III

    Your phone, your food, and the fuel that powers your car all depend on oil-derived petrochemicals. But experts anticipate oil reserves will run dry as early as 2070, forcing industries dependent on petrochemicals to look for alternatives that would fundamentally change the way they do business–and the way we live.

    But scientists like Kate Adamala (BTI/Genetics, Cell Biology and Development) see another path forward. They envision a world where oil reserves disappear but one where we’ll still be able to meet our need for petrochemicals. Their solution? Create more life.

    Adamala, a chemical engineer by training, is working to build living organisms from nonliving chemical components. These “synthetic cells” can help scientists explore the origin of life, accelerate drug discovery, or provide a renewable source of resources, like petrochemicals.

    At its core, a synthetic cell is an organism that exhibits lifelike qualities. Much like a car, which is a collection of metal parts until arranged in the right way, cells are chemical bundles organized in a particular manner. Adamala constructs synthetic cells in her lab by encapsulating nucleic acids, amino acids, and ribosomes (the building blocks of cellular life) within a protective lipid coating. This method, known as the “bottom-up” approach, offers a key advantage: complete control over the cell’s components.

    Natural cells can also be engineered to perform specific functions, but they’re resistant to change, and coaxing them into producing large quantities of desirable chemicals comes at a cost. When scientists engineer cells to create petrochemicals, for example, the build-up of those chemicals can damage the cell. “No self-respecting cell will make those chemicals because it’s toxic to them.”

    Synthetic cells, however, are a blank slate. “Because we make them from scratch, they don’t have the baggage of 4 billion years of evolution,” Adamala remarks. They can be manufactured to do what scientists want them to do (like churning out petrochemicals). But, even with this level of control, there are still compromises. Adamala likens this to canine domestication. “I want my dog to sit on my lap and keep me warm in the winter. And he does that, but he cannot go out and hunt … so that’s the trade-off we made.”

    Before synthetic cells can support a robust biomanufacturing economy, scientists like Adamala also need to resolve the physics of how cells self-replicate. To date, researchers have yet to determine how to make synthetic cells reproduce on their own–a crucial step toward using these organisms as in mini, living biofactories.

    Like many scientists, Adamala grew up watching science fiction films and was fascinated by the search for life beyond earth. She earned her Ph.D. in astrobiology, but synthetic biology allowed her to explore her passion while producing tangible benefits for society. “The synthetic cell engineering field presented itself as everything I always wanted. It has connections to origins and astrobiology, so I can still say I’m looking for life on Mars! But it’s also incredibly applicable. It could solve some of the biggest problems our economy is facing now.”

    Adamala isn’t the only scientist excited about this approach to cell engineering. The Build-a-Cell consortium, co-founded and led by Adamala, intends to construct a network of scientists sharing ideas, data, success stories, and failures–not unlike open-source software platforms that depend on shared knowledge to drive innovation. Adamala is hopeful that by uniting researchers via Build-a-Cell, they’ll get there sooner rather than later.

    Once we unlock their potential, synthetic cells could produce fuel for our cars, fibers for clothing, and fertilizers to increase crop yields. They may also accelerate biomedical discovery or offer a glimpse into the life of our earliest ancestors. One day, they may even enable us to survive on Mars.

    The DNA Solution

    The DNA Solution

    The DNA Solution

    Synthetic biology is poised to revolutionize everything from health care to climate change—and Michael Smanski is making the most of it.

    By Mary Hoff

    The exploding yeast and fluorescent fish are interesting, for sure. But for Michael Smanski, the real attraction of synthetic biology is the chance to work at the cusp of a new era in biology—one that holds promise for improving food production, medical care, climate change adaptation, pollution cleanup and more.

    Living things use DNA as a template for creating proteins, which in turn control the processes that make life possible. Synthetic biology creates new forms of DNA and enlists microbes, plants, or other organisms to use these new forms to produce products or functions beneficial to humans.  

    “Twenty years ago, the field of biology went through an interesting phase change that was catalyzed by the Human Genome Project: the ability to read DNA. And it touched every area of biology,” says Smanski, McKnight Land Grant professor in the College of Biological Sciences “The phase change we’re going through now is even more exciting than that—and that’s the ability to write with DNA. It’s changing biology from a descriptive science, where we’re trying to learn about nature, to an engineering science, where we can ask, ‘What can life be programmed to do?’”

    In Smanski’s case, the answer to that question appears virtually boundless. Trained as a biochemist and bacteriologist, he came to the University in 2014 because of its strength in both engineering and the natural sciences. In the few short years since, both synthetic biology and his research have expanded dramatically. Assembling a team of postdoctoral fellows and graduate students with expertise in computer science, chemistry and engineering as well as biology, he began exploring strategies for creating DNA-based assembly lines that microbes could use to make materials useful for humans.

    In one line of research, he and his colleagues have been working to optimize a bacteria-based system that produces drugs to treat disorders such as stroke or Parkinson’s disease. In another, he has led development of a novel strategy for ensuring that engineered organisms can’t produce viable progeny with their wild relatives (hence the exploding yeast).

    More recently, Smanski has begun applying synthetic biology to more complex organisms, such as vascular plants, insects, and vertebrates. By modifying their genomes to incorporate useful traits while also removing their ability to breed with unmodified relatives, he’s creating innovative strategies for controlling disease-causing and ecosystem-disrupting pests without resorting to poisons.

    “We have a few projects in plants to try to translate this for agriculture,” he says. Novoclade, a University biotech startup he helped found and for which he serves as chief technology officer, is exploring applications for controlling mosquitoes and stopping the spread of invasive carp (hence the fluorescent fish).

    Some of the biggest challenges related to his work are not about altering molecules and coaxing them to perform desired tasks. Rather, they relate to the kinds of issues entrepreneurs encounter with any new technology: making sure they’re addressing real needs; identifying and mitigating potential unintended consequences, complying with regulatory constraints, listening and incorporating input from various stakeholders, scaling, and more. So, for instance, he’s involved in a national Manufacturing Innovation Institute called BioMADE that’s working to bridge the large and often unwieldy gap between being able to do something in a laboratory and being able to do it on a commercial scale. And he’s consulting with the Minnesota Department of Natural Resources, tribal governments, and others to ensure their concerns are addressed and their needs are met with his carp work.

    “We think a lot about translating these technologies to the field and trying to do it responsibly, because we don’t want to develop a technology that the public doesn’t want,” he says. “We’re not just teaching people, we’re learning from them in ways that helps guide the direction that we take.”

    As he sets his sights on new directions, Smanski is excited about the College of Biological Sciences’ recently announced efforts to make the University of Minnesota an international hub for frontline synthetic biology research and development. 

    “We’re excited to see the details emerge,” he says. “There are so many interesting directions that the field can take right now”—from advancing and applying the new tools to engineering a person’s cells to fight cancer, to reducing waste in food production, producing materials to replace climate-disrupting fossil fuels, developing crops that can thrive in the face of climate change and more.

    As far as what’s next for the Smanski lab—even Smanski himself suspects it’s beyond imagination.

    “Throughout my career and throughout the time frame of my lab, we let the science take us in the most interesting directions,” he says. “We’re going to keep going where the science leads us.”

    Art Edison

    Art Edison

    Art Edison

    University of Georgia

    Unique strengths of NMR metabalomics: In vivo metabolism & improved compound identification

    Metabolomics is an important component of systems biology research in biology and biomedicine. Two major technologies are widely used in metabolomics research, mass spectrometry and NMR spectroscopy. Both have their own strengths and weaknesses. Recently, LC-MS has gained in popularity, thanks largely to its high sensitivity and ability to detect 10s of thousands of features.

    In this talk, I will highlight some of the unique strengths of NMR metabolomics, most notably approaches to study metabolic dynamics in real-time in cells or microorganisms. I will also discuss the difficulty that the entire field faces in confident metabolite identification and will present recent approaches to better combine NMR with LC-MS and computational chemistry to improve compound identification.

    THURSDAY  I  SEPT. 29 I  3:30-4:30 PM CST  I  HYBRID SEMINAR